Bal Pharma Limited has released its unaudited standalone financial results for the first quarter of FY27, ending June 30, 2026. The Board of Directors approved the results in a meeting held on August 12, 2026. While specific financial metrics were not detailed in the immediate press release, the full format of the results is available on the company’s website and stock exchange portals.

In a separate compliance move, the company issued a notice regarding the transfer of unclaimed equity shares to the Investor Education and Protection Fund (IEPF) Authority. Under Sections 124 and 125 of the Companies Act, 2013, shares belonging to shareholders who have not claimed dividends for seven consecutive years are liable for transfer.

Key Compliance Details

The notice applies to dividends declared from FY2018-19 onwards. Shareholders affected by this provision must take action to retain their holdings:

• Deadline: Claims must be submitted on or before October 30, 2026.
• Action Required: Shareholders must apply to the Registrar and Transfer Agents (RTA), M/s. TSR Consultants Private Limited.
• Consequence: Failure to claim shares and dividends by the deadline will result in the transfer of these assets to the demat account of the IEPF Authority.

The company emphasized that no claims will lie against Bal Pharma or its RTA for amounts or shares transferred to the IEPF after the deadline. However, shareholders can still recover their assets by following the procedure stipulated in the IEPF Rules.

What the Numbers Show

The release of Q1FY27 results coincides with significant regulatory compliance actions regarding dormant shareholder accounts. This dual announcement highlights the company's focus on both operational transparency through quarterly reporting and statutory adherence to investor protection norms. The strict October deadline underscores the urgency for long-term investors to verify their dividend claim status.

Bal Pharma Limited has opened a 48-hour window for shareholders to submit comments, observations, or objections regarding a corrigendum to its postal ballot notice, which revised the issue price of convertible warrants to ₹84 from ₹81. The company, Bal Pharma , issued this intimation on July 30, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, to ensure transparency and provide an additional opportunity for members who had already voted before the corrigendum was issued on July 23, 2026. This procedural step allows shareholders to formally record any concerns about the modifications, which include adjusted payment terms and valuation metrics for the proposed preferential issue.

The remote e-voting facility for the postal ballot remains open until 5:00 P.M. IST on August 8, 2026. Shareholders who cast their votes prior to the issuance of the corrigendum are permitted to revise or modify their votes in accordance with the specified procedure. The company emphasized that this extended opportunity is designed to facilitate informed decision-making, particularly for those who acted before the latest disclosures were made available. The corrigendum itself was issued following clarifications sought by the National Stock Exchange of India Limited (NSE) and BSE Limited under the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Revised Warrant Pricing and Valuation

The core modification in the corrigendum raises the issue price of the convertible warrants to ₹84 per warrant. This adjustment increases the total potential capital raise to ₹8.4 crore, earmarked for a greenfield Active Pharmaceutical Ingredients (API) manufacturing facility in Yadgiri, Karnataka. The new price includes a premium of ₹74 per warrant and aligns with regulatory requirements based on valuation reports. An independent registered valuer, Mr. CA S. Bhaskar, determined the fair value using multiple approaches. The market approach yielded the highest value of ₹83.869 per equity share, which also matched the 90-day volume-weighted average price on the NSE, establishing the regulatory floor price.

The company opted for the slightly higher price of ₹84 to ensure compliance and reflect fair value. Consequently, the payment structure for the 10,00,000 warrants has been adjusted. Warrant holders must pay 25% of the consideration, amounting to ₹21 per warrant, on the date of allotment. The remaining 75%, or ₹63 per warrant, is due before the conversion of warrants into equity shares.

Project Utilization and Shareholding Impact

Proceeds from the warrant issue are exclusively allocated to the API manufacturing project in Yadgiri. Bal Pharma has acquired approximately 5 acres of land through the Karnataka Industrial Areas Development Board (KIADB) and obtained prior environmental clearance from the Ministry of Environment, Forest and Climate Change (MoEF&CC). The total project cost is estimated at approximately ₹300 crore, with the ₹8.4 crore from this issue covering initial capital expenditures such as construction and machinery installation. The company intends to utilize these funds by December 31, 2027.

Upon full conversion of the 10,00,000 warrants and 10,00,000 employee stock options, the promoter holding of Mr. Shailesh Siroya will increase from 17.24% to 20.89% of the total equity. The overall promoter group holding will remain stable at approximately 50.76% on a fully diluted basis. The company confirmed that there will be no change in management or control, and the transaction complies with SEBI’s Substantial Acquisition of Shares and Takeovers (SAST) Regulations.